{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:46:41Z","timestamp":1791956801128,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40121-026-01424-2","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:07:10Z","timestamp":1788437230000},"page":"3017-3032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Characteristics, Healthcare Utilization, and Treatment Patterns Among People Living with HIV by Antiretroviral Therapy Use in the USA, 2021\u20132024"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7448-1976","authenticated-orcid":false,"given":"Moti","family":"Ramgopal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2744-4918","authenticated-orcid":false,"given":"Jacob","family":"Lalezari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7010-2024","authenticated-orcid":false,"given":"Carrie","family":"Huisingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9982-8160","authenticated-orcid":false,"given":"Yunhua","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5817-7365","authenticated-orcid":false,"given":"Arlene","family":"Nugent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6168-6745","authenticated-orcid":false,"given":"Chloe","family":"Orkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3458-1539","authenticated-orcid":false,"given":"Karine","family":"Dub\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7990-6831","authenticated-orcid":false,"given":"Kimmie","family":"Pringle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8668-3898","authenticated-orcid":false,"given":"Liza Bronner","family":"Murrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"1424_CR1","unstructured":"Estimated HIV incidence and prevalence in the United States, 2018\u20132022. HIV Surveillance Supplemental Report 2024;29 (No. 1). Accessed 7 July 2025. https:\/\/www.cdc.gov\/hiv-data\/nhss\/estimated-hiv-incidence-and-prevalence.html"},{"key":"1424_CR2","unstructured":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization. 2021. Accessed 7 July 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240031593"},{"key":"1424_CR3","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. 2024. Accessed 7 July 2025. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv."},{"issue":"12","key":"1424_CR4","first-page":"580","volume":"25","author":"JL Priest","year":"2019","unstructured":"Priest JL, Burton T, Blauer-Peterson C, Andrade K, Oglesby A. Clinical characteristics and treatment patterns among US patients with HIV. Am J Manag Care. 2019;25(12):580\u20136.","journal-title":"Am J Manag Care"},{"issue":"2","key":"1424_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40121-018-0201-6","volume":"7","author":"A Chawla","year":"2018","unstructured":"Chawla A, Wang C, Patton C, et\u00a0al. A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population. Infect Dis Ther. 2018;7(2):183\u201395. https:\/\/doi.org\/10.1007\/s40121-018-0201-6.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"1424_CR6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/1471-2334-12-296","volume":"12","author":"MC Prosperi","year":"2012","unstructured":"Prosperi MC, Fabbiani M, Fanti I, et\u00a0al. Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infect Dis. 2012;12(1):296. https:\/\/doi.org\/10.1186\/1471-2334-12-296.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"1424_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s41669-020-00209-8","volume":"4","author":"JP Cohen","year":"2020","unstructured":"Cohen JP, Beaubrun A, Ding Y, Wade RL, Hines DM. Estimation of the incremental cumulative cost of HIV compared with a non-HIV population. Pharmacoecon Open. 2020;4(4):687\u201396. https:\/\/doi.org\/10.1007\/s41669-020-00209-8.","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"1424_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/03007995.2017.1383889","volume":"34","author":"J Gallant","year":"2018","unstructured":"Gallant J, Hsue P, Budd D, Meyer N. Healthcare utilization and direct costs of non-infectious comorbidities in HIV-infected patients in the USA. Curr Med Res Opin. 2018;34(1):13\u201323. https:\/\/doi.org\/10.1080\/03007995.2017.1383889.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"1424_CR9","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/qad.0b013e32835cb997","volume":"27","author":"S Abgrall","year":"2013","unstructured":"Abgrall S, Ingle SM, May MT, et\u00a0al. Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002\u20132009. AIDS. 2013;27(5):803\u201313. https:\/\/doi.org\/10.1097\/qad.0b013e32835cb997.","journal-title":"AIDS"},{"issue":"1","key":"1424_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/archinternmed.2009.432","volume":"170","author":"L Elzi","year":"2010","unstructured":"Elzi L, Marzolini C, Furrer H, et\u00a0al. Treatment modification in human immunodeficiency virus\u2013infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010;170(1):57\u201365. https:\/\/doi.org\/10.1001\/archinternmed.2009.432.","journal-title":"Arch Intern Med"},{"issue":"1","key":"1424_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12981-020-00268-1","volume":"17","author":"J Cohen","year":"2020","unstructured":"Cohen J, Beaubrun A, Bashyal R, Huang A, Li J, Baser O. Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US Medicaid beneficiaries. AIDS Res Ther. 2020;17(1):12. https:\/\/doi.org\/10.1186\/s12981-020-00268-1.","journal-title":"AIDS Res Ther"},{"issue":"12","key":"1424_CR12","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1007\/s10461-020-02937-8","volume":"24","author":"C Benson","year":"2020","unstructured":"Benson C, Wang X, Dunn KJ, et\u00a0al. Antiretroviral adherence, drug resistance, and the impact of social determinants of health in HIV-1 patients in the US. AIDS Behav. 2020;24(12):3562\u201373. https:\/\/doi.org\/10.1007\/s10461-020-02937-8.","journal-title":"AIDS Behav"},{"issue":"9","key":"1424_CR13","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1007\/s12325-021-01883-8","volume":"38","author":"GA McComsey","year":"2021","unstructured":"McComsey GA, Lingohr-Smith M, Rogers R, Lin J, Donga P. Real-world adherence to antiretroviral therapy among HIV-1 patients across the United States. Adv Ther. 2021;38(9):4961\u201374. https:\/\/doi.org\/10.1007\/s12325-021-01883-8.","journal-title":"Adv Ther"},{"issue":"6","key":"1424_CR14","doi-asserted-by":"publisher","first-page":"e21748","DOI":"10.1371\/journal.pone.0021748","volume":"6","author":"T Antoniou","year":"2011","unstructured":"Antoniou T, Zagorski B, Loutfy MR, Strike C, Glazier RH. Validation of case-finding algorithms derived from administrative data for identifying adults living with human immunodeficiency virus infection. PLoS One. 2011;6(6):e21748. https:\/\/doi.org\/10.1371\/journal.pone.0021748.","journal-title":"PLoS One"},{"issue":"8","key":"1424_CR15","doi-asserted-by":"publisher","first-page":"e0290777","DOI":"10.1371\/journal.pone.0290777","volume":"18","author":"SD Emerson","year":"2023","unstructured":"Emerson SD, McLinden T, Sereda P, et\u00a0al. Identification of people with low prevalence diseases in administrative healthcare records: a case study of HIV in British Columbia, Canada. PLoS One. 2023;18(8):e0290777. https:\/\/doi.org\/10.1371\/journal.pone.0290777.","journal-title":"PLoS One"},{"key":"1424_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","volume":"79","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Sauer BC, Hern\u00e1ndez-D\u00edaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70\u20135. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.04.014.","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"1424_CR17","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2019.1343","volume":"321","author":"AS Fauci","year":"2019","unstructured":"Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic. JAMA. 2019;321(9):844\u20135. https:\/\/doi.org\/10.1001\/jama.2019.1343.","journal-title":"JAMA"},{"issue":"1","key":"1424_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/qai.0000000000000084","volume":"66","author":"AJ Hughes","year":"2014","unstructured":"Hughes AJ, Mattson CL, Scheer S, Beer L, Skarbinski J. Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States. J Acquir Immune Defic Syndr. 2014;66(1):80\u20139. https:\/\/doi.org\/10.1097\/qai.0000000000000084.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"1424_CR19","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1097\/qad.0000000000002210","volume":"33","author":"L Bansi-Matharu","year":"2019","unstructured":"Bansi-Matharu L, Loria GR, Cole SR, et\u00a0al. Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiators. AIDS. 2019;33(8):1385\u201390. https:\/\/doi.org\/10.1097\/qad.0000000000002210.","journal-title":"AIDS"},{"issue":"1","key":"1424_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12981-025-00813-w","volume":"22","author":"F Jing","year":"2025","unstructured":"Jing F, Jing P, Yuan C, Yanni L, Xingming H. Attrition rate of antiretroviral therapy and its influencing factors among Chinese people living with HIV\/AIDS: a meta-analysis and system review. AIDS Res Ther. 2025;22(1):125. https:\/\/doi.org\/10.1186\/s12981-025-00813-w.","journal-title":"AIDS Res Ther"},{"issue":"Suppl 1","key":"1424_CR21","doi-asserted-by":"publisher","first-page":"A187","DOI":"10.1136\/ejhpharm-2018-eahpconf.404","volume":"25","author":"TV Lopez","year":"2018","unstructured":"Lopez TV, de Molina MDLM, de Vicente MST, Donoso JLS, Torres I, Parada JH. 5PSQ-050 Neuropsychiatric adverse effects on dolutegravir: experience in a third-level hospital. Eur J Hosp Pharm. 2018;25(Suppl 1):A187\u20139. https:\/\/doi.org\/10.1136\/ejhpharm-2018-eahpconf.404.","journal-title":"Eur J Hosp Pharm"},{"issue":"3","key":"1424_CR22","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3390\/v15030720","volume":"15","author":"A De Vito","year":"2023","unstructured":"De Vito A, Ricci E, Menzaghi B, et\u00a0al. Causes of HIV treatment interruption during the last 20 years: a multi-cohort real-life study. Viruses. 2023;15(3):720. https:\/\/doi.org\/10.3390\/v15030720.","journal-title":"Viruses"},{"issue":"11","key":"1424_CR23","doi-asserted-by":"publisher","first-page":"e1002434","DOI":"10.1371\/journal.pmed.1002434","volume":"14","author":"IT Katz","year":"2017","unstructured":"Katz IT, Kaplan R, Fitzmaurice G, et\u00a0al. Treatment guidelines and early loss from care for people living with HIV in Cape Town, South Africa: a retrospective cohort study. PLoS Med. 2017;14(11):e1002434. https:\/\/doi.org\/10.1371\/journal.pmed.1002434.","journal-title":"PLoS Med"},{"issue":"8","key":"1424_CR24","doi-asserted-by":"publisher","first-page":"817","DOI":"10.18553\/jmcp.2024.30.8.817","volume":"30","author":"A Colson","year":"2018","unstructured":"Colson A, Chastek B, Gruber J, et\u00a0al. Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018. J Manag Care Spec Pharm. 2018;30(8):817\u201324. https:\/\/doi.org\/10.18553\/jmcp.2024.30.8.817.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"1424_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/QAI.0000000000003124","volume":"92","author":"WG El-Nahal","year":"2021","unstructured":"El-Nahal WG, Chander G, Jones JL, et\u00a0al. Telemedicine use among people with HIV in 2021: the hybrid-care environment. J Acquir Immune Defic Syndr. 2021;92(3):223\u201330. https:\/\/doi.org\/10.1097\/QAI.0000000000003124.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1424_CR26","unstructured":"Monitoring selected national HIV prevention and care objectives by using HIV surveillance data\u2014United States and 6 dependent areas, 2020. HIV Surveillance Supplemental Report 2022;27(No. 3). Accessed 7 July 2026. http:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance.html."},{"key":"1424_CR27","doi-asserted-by":"publisher","first-page":"04078","DOI":"10.7189\/jogh.14.04078","volume":"14","author":"S Zhu","year":"2024","unstructured":"Zhu S, Wang W, He J, et\u00a0al. Higher cardiovascular disease risks in people living with HIV: a systematic review and meta-analysis. J Glob Health. 2024;14:04078. https:\/\/doi.org\/10.7189\/jogh.14.04078.","journal-title":"J Glob Health"},{"issue":"12","key":"1424_CR28","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/cid\/ciw125","volume":"62","author":"A Low","year":"2016","unstructured":"Low A, Gavriilidis G, Larke N, et\u00a0al. Incidence of opportunistic infections and the impact of antiretroviral therapy among HIV-infected adults in low- and middle-income countries: a systematic review and meta-analysis. Clin Infect Dis. 2016;62(12):1595\u2013603. https:\/\/doi.org\/10.1093\/cid\/ciw125.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1424_CR29","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/infdis\/jiw086","volume":"214","author":"F Hansjakob","year":"2016","unstructured":"Hansjakob F. Opportunistic diseases during HIV infection\u2014Things aren\u2019t what they used to be, or are they? J Infect Dis. 2016;214(6):830\u20131. https:\/\/doi.org\/10.1093\/infdis\/jiw086.","journal-title":"J Infect Dis"},{"issue":"8","key":"1424_CR30","doi-asserted-by":"publisher","first-page":"ofac336","DOI":"10.1093\/ofid\/ofac336","volume":"9","author":"J Li","year":"2012","unstructured":"Li J, Humes E, Lee JS, et\u00a0al. Toward ending the HIV epidemic: temporal trends and disparities in early ART initiation and early viral suppression among people newly entering HIV care in the United States, 2012\u20132018. Open Forum Infect Dis. 2012;9(8):ofac336. https:\/\/doi.org\/10.1093\/ofid\/ofac336.","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"1424_CR31","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/pds.3458","volume":"22","author":"JC Lauffenburger","year":"2013","unstructured":"Lauffenburger JC, Balasubramanian A, Farley JF, et\u00a0al. Completeness of prescription information in US commercial claims databases. Pharmacoepidemiol Drug Saf. 2013;22(8):899\u2013906. https:\/\/doi.org\/10.1002\/pds.3458.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1424_CR32","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/s0895-4356(00)00259-6","volume":"53","author":"DA McKenzie","year":"2000","unstructured":"McKenzie DA, Semradek J, McFarland BH, Mullooly JP, McCamant LE. The validity of medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol. 2000;53:1248\u201357. https:\/\/doi.org\/10.1016\/s0895-4356(00)00259-6.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"1424_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1089\/apc.2016.0178","volume":"31","author":"PF Rebeiro","year":"2017","unstructured":"Rebeiro PF, Abraham AG, Horberg MA, et\u00a0al. Sex, race, and HIV risk disparities in discontinuity of HIV care after antiretroviral therapy initiation in the United States and Canada. AIDS Patient Care STDS. 2017;31(3):129\u201344. https:\/\/doi.org\/10.1089\/apc.2016.0178.","journal-title":"AIDS Patient Care STDS"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01424-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01424-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01424-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:02:35Z","timestamp":1791954155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01424-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1424"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01424-2","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Moti Ramgopal has received consulting fees from Gilead Sciences, Merck, and ViiV Healthcare and honoraria from AbbVie, Gilead Sciences, Janssen, and ViiV Healthcare outside the submitted work. Jacob Lalezari has no disclosures to announce. Chloe Orkin provides advisory services and receives lecture fees and research grants from Gilead Sciences, ViiV Healthcare, MSD, and Bavarian Nordic. Karine Dub\u00e9 provides advisory services to AbbVie, Gilead Sciences, and ViiV Healthcare. Carrie Huisingh, Yunhua Fan, Arlene Nugent, Kimmie Pringle, and Liza Murrison are employees of AbbVie and may own stock or stock options.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This observational study utilized secondary, de-identified health claims data with no potential for patient identification and therefore did not require approval from an institutional review board or informed consent from patients.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}